A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
83actual
Sites
61
Countries
Australia, Canada, China +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-05 | actual | When the study began enrolling |
| Primary completion | 2025-07-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-18 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Hepatocellular
Interventions
- Drug: Relatlimab — also filed as BMS-986016
- Drug: Nivolumab — also filed as BMS-936558, Opdivo
- Drug: Bevacizumab — also filed as Avastin
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFIncidence of dose-limiting toxicities (DLTs)
measured Up to 6 weeks
Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
measured Assessed up to 3 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed